Login
Companies $TECH
$72.74 -$0.05 (0.07%) After hours
BIO-TECHNE Corp logo

BIO-TECHNE Corp

bio-techne.com

What Do They Do?

Sells biological reagents, protein-analysis instruments and diagnostic products to academic and industry researchers, pharmaceutical and biotechnology companies, and clinical laboratories.

How Do They Make Money?

Customers buy consumables and most instruments as shipped goods; service arrangements may be paid in advance, on completion or in both stages, and royalties follow sales.

revenue
SegmentShareRevenue
Protein Sciences
Sold outright

72%
FY2023: 74%
Diagnostics and Spatial Biology
Sold outright

28%
FY2023: 26%

Who Are Their Customers?

Academic and industry researchers buy directly and through distributors; pharmaceutical and biotech customers also buy research and therapy-development products, while instrument makers purchase many diagnostic controls and reagents through OEM agreements.

Do Revenues Turn Into Profits?

Yes. It kept 15 cents of every revenue dollar as net income in FY2026 and turned 22 cents into free cash flow.

Operating income, FY2026
21% of revenue
โ–ฒ +146% vs FY2025 ($102.3M, 8%)
Net income, FY2026
15% of revenue
โ–ฒ +148% vs FY2025 ($73.4M, 6%)
Free cash flow, FY2026
22% of revenue
โ–ฒ +3% vs FY2025 ($256.6M, 21%)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Revenue
โ–ฒ +5%
vs $286.6M in Q1 FY2026
Net income
โ–ผ โˆ’26%
vs $38.2M in Q1 FY2026
Protein Sciences share of revenue vs 70.6% in Q1 FY2026
  • Sep 23, 2026 Shareholders approved Merck's proposed acquisition The company said closing remained subject to remaining regulatory approvals.

Growing. Revenue grew 10% in 4 years, from $1.1B in FY2022 to $1.2B in FY2026, about 2% a year.

Exosome Diagnostics divestiture The older report described the ExoDx and ExoTRU tests under Exosome Diagnostics; the latest report says Bio-Techne divested Exosome Diagnostics.

Revenue over time
Protein Sciences Diagnostics and Spatial Biology Diagnostics and Genomics
$2B$1B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support